Jan 18, 2023 / 03:00PM GMT
Kalpit R. Patel - B. Riley Securities, Inc., Research Division - Healthcare Research Analyst
Okay. Good morning, everyone, and welcome to B. Riley's Oncology Conference. I'm Kalpit Patel, a research analyst here at B. Riley. And it's my pleasure to introduce our first fireside chat of the day, with Allogene's CFO, Eric Schmidt.
If anyone in the audience has any questions for Eric, please feel free to e-mail me at [email protected].
Eric, it's great to have you join us today. Welcome.
Questions and Answers:
Kalpit R. Patel - B. Riley Securities, Inc., Research Division - Healthcare Research AnalystMaybe to start, let's dive right into the data that you've showed at your November R&D showcase. I want to specifically dig into the durability data that you've shown for ALLO-501, 501A. There was a nice slide in there with the swimmers plot that was outlined, which essentially showed how patients performed over a long period of time, the patients who achieved a CR.
Can you give us a sense of how closely this durability
Trustpilot
